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In 1992 and 1993, we published two papers that de- 
scribed the structure of the Src homology 2 (SH2) do- 
main of the v-Src tyrosine kinase complexed to nonspe- 
cific phosphotyrosyl peptides (Waksman et al., 1992) 
and to a phosphopeptide that has specificity for the Src 
SH2 domain (Waksman et al., 1993). These papers mark 
the beginnings of a research effort on the Src kinases 
that has resulted ten years later in the structure of the 
autoinhibited form of the Src relative c-Abl, providing 
an explanation for how the different utilization of the 
SH2 domain in c-Abl and c-Src underlies the ability of 
the cancer drug Gleevec to inhibit Abl but not Src (Nagar 
et al., 2003). In this commentary, we discuss how our 
initial experiments on Src began and describe some of 
the factors that led to the rapid determination of the 
SH2 structure. 
The SH2 (Src homology 2) domain was discovered by 
Tony Pawson in 1986, who identified it as a block of 
sequence spanning approximately 100 residues that is 
conserved amongst v-Src and other nonreceptor tyro- 
sine kinases (Sadowski et al., 1986). Pawson's early 
studies indicated that the SH2 domain, located up- 
stream of the catalytic domain in Src and related tyrosine 
kinases, is not essential for catalytic activity but ap- 
peared instead to play a role in the regulation of the 
signaling properties of these proteins. Work in the Hana- 
fusa laboratory on the newly discovered v-crk oncogene 
led to the identification of a second modular domain, 
named SH3, that often works in concert with SH2 do- 
mains (Mayer et al., 1988). We were particularly excited 
by the discovery of v-Crk, since this protein contains 
only SH2 and SH3 domains, and yet was capable of 
binding to tyrosine phosphorylated proteins and stimu- 
lating tyrosine kinase activity in cells (Matsuda et al., 
1990; Mayer and Hanafusa, 1990). Studies on v-Crk and 
also on the epidermal growth factor (EGF) receptor and 
the platelet-derived growth factor (PDGF) receptors es- 
tablished that SH2 domains bind to phosphorylated ty- 
rosine residues, making the SH2 domain the first of the 
modular targeting devices to be discovered and charac- 
terized (Anderson et al., 1990; Kazlauskas et al., 1990; 
Matsuda et al., 1990; Moran et al., 1990). This marked 
a profound shift in how we think about intracellular sig- 
naling, since receptor-mediated protein clustering is a 
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mechanism that contrasts markedly with signal propa- 
gation mechanisms that rely on the diffusion of small 
molecule second messengers. 
The late 1980s also saw major advances in our under- 
standing of how the tyrosine kinases of the Src family 
are regulated. An intramolecular interaction between a 
phosphotyrosine residue in the C-terminal tail of the 
Src protein was shown to inactivate the tyrosine kinase 
domain (see Roussel et al., 1991 and references therein; 
reviewed in Thomas and Brugge, 1997). Thus, a dual 
role for the Src SH2 domain in "turning inwards" and 
regulating the kinase activity of Src and "turning out- 
wards" and directing the appropriate localization of Src 
kinases emerged from these studies. The race was on 
to determine the three-dimensional structure of the SH2 
domain and to more clearly map out its function. 
In the late 1980s and early 1990s, when these hypothe- 
ses regarding Src kinase regulation were being vali- 
dated, our concept of the modular "mix and match" 
architecture of complex proteins was still relatively un- 
formed. Studies in transcription had prepared us for 
the idea that complex proteins are constructed from 
relatively independent domains with distinct functions, 
as witnessed by the separability of the DNA binding and 
other functional domains of many transcription factors 
(an early demonstration of this principle is given by Pabo 
et al., 1979). Nevertheless, our view of protein structure 
in the 1980s remained focused on the tightly integrated 
architecture of autonomous functional units, whether 
complex or simple. In this regard, we did not know quite 
what to make of the SH2 domain: was it reasonable 
to think of it as a separable functional module, as the 
biological experiments were beginning to suggest? Or 
would the very act of pulling the domain out of its proper 
context scramble its proper function? 
Prior to the early 1990s attempts to determine the 
structures of large and complex proteins often met with 
failure. One central problem that was not always recog- 
nized at that time is that flexible segments or linkages 
can be a severe impediment o crystallization. Flexible 
linkages in proteins can be mapped using limited prote- 
ase digestion, a classical method that is still an impor- 
tant component of the biochemist's tool kit. Despite the 
ease with which this method can be applied, it is difficult 
to obtain precise molecular boundaries without high- 
resolution mass spectrometric analysis of the resulting 
fragments. The application of mass spectrometry to pro- 
tein analysis was gaining momentum in the late 1980s, 
but when we began our studies on the SH2 domain 
mass spectrometry was not quite ready for mapping 
domain boundaries in a routine manner. 
What really got the structural analysis of the Src SH2 
domain off to a flying start despite these various sources 
of confusion was the fact that so many proteins that are 
functionally unrelated to tyrosine kinases were found to 
contain SH2 domains (Koch et al., 1991). These included 
phosphatidyl inositol 3-OH kinase, phospholipase C~/1, 
ras GTPase-activating protein (Ras-GAP), and certain 
protein tyrosine phosphatases. The presence of clearly 
recognizable SH2 domains in such diverse backgrounds 
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suggested strongly that the domain is indeed an inde- 
pendently folding unit, with boundaries that are readily 
defined. We now know that many SH2 domains are quite 
divergent in sequence from the canonical ones and had 
these been included the definition of the domain bound- 
aries would not have been so easy. Indeed, some SH2 
domains, such as those in the STAT proteins, cannot 
be separated from their parent proteins without struc- 
tural disruption. 
Our good fortune in being able to pick the correct 
boundaries of the SH2 domain was followed by a bo- 
nanza in protein expression. Using a standard bacterial 
expression system with no affinity tags, we were able to 
routinely purify tens of milligrams of soluble SH2 domain 
from one liter of bacterial culture. This breakthrough 
occurred at a time when structural biology groups, such 
as ours, were making important strategic changes in 
how we approached the expression and pudfication of 
target proteins. In the past, purified protein would be 
delivered to us by our collaborators or, in some cases, 
we would purify proteins ourselves, but use expression 
constructs that had been developed by our collabora- 
tors. Relatively little thought was given to the definition 
of the protein construct used and hardly any to what 
comparative sequence analysis might teach us about 
how best to tackle the protein. As we developed plans 
to work on the Src kinases it became clear that a suc- 
cessful approach would have to marry molecular biology 
to protein expression and purification right from the 
start. One of us (G.W.) had been trained as a molecular 
biologist and came to the Rockefeller University to apply 
molecular biology to a structural attack on the Src prob- 
lem in the nascent research group of the other (J.K.). 
The Rockefeller University was a particularly stimulating 
environment for thinking about how best to solve the 
Src structure. In addition to Hidesaburo Hanafusa, who 
was our main source for guidance and insight, we en- 
gaged in many discussions with David Cowbum, who 
began an analysis of the Abl SH2 domain by NMR in 
collaboration with David Baltimore (then at the Rockefel- 
ler University) and his postdoctoral fellow Bruce Mayer 
(formerly a student of Hanafusa's) and Marilyn Resh 
(at Memorial Sloan-Kettering Cancer Center, across the 
street from us). 
We began by trying to crystallize the Src SH2 domain 
by itself, and relatively quickly obtained large crystals 
that diffracted X-rays to high resolution (better than 
1.5 A). Our initial excitement at seeing the spectacular 
extent of the first diffraction patterns quickly changed 
to chagrin when we realized that the diffraction patterns 
indicated a critical flaw in the crystals: along certain 
directions the diffraction pattern consisted of rows of 
sharp spots (a characteristic feature of X-ray diffraction 
from nicely ordered crystals) alternating with rows of 
diffraction lines that were not clearly resolved into indi- 
vidual spots. No matter what we tried we could not 
resolve individual spots within these alternating rows of 
streaky diffraction, and we had to conclude reluctantly 
that our crystals were intrinsically disordered in some 
way. An intensive hunt for an alternate crystal form led 
to the discovery that the addition of phosphate ions 
led to crystals that diffracted X-rays to not as high a 
resolution (2.5 A), but without any evidence for the 
streaky diffraction that had plagued our analysis of the 
earlier crystals. Unfortunately, these crystals were so 
sensitive to handling that we could not proceed with 
structure determination at that time, although we did 
eventually return to these crystals to obtain the structure 
of the uncomplexed SH2 domain, described in our 1993 
Cell paper. 
These problems with the Src SH2 crystals suggested 
that we needed to stabilize the protein molecule in some 
way, and the obvious route to this would be to add 
a peptide ligand. High-affinity ligands for the Src SH2 
domain were not known at that time (the tail of c-Src 
relies on local concentration to achieve its effects, and 
is not by itself a high affinity ligand for the SH2 domain). 
Fortunately for us, David Cowburn and his postdoctoral 
fellow Nalin Pant were synthesizing phosphotyrosyl 
peptides corresponding to the SH2 binding sites on the 
PDGF and EGF receptors (Kashishian et al., 1992; Mar- 
golis et al., 1989). Cowbum suggested to us that we 
ignore the fact that these peptides were probably not 
the biologically relevant argets for the Src SH2 domain, 
and add them to our crystallization mixtures. We did so, 
with some misgivings, but the results were remarkable: 
within hours of the addition of these peptides to the 
crystallization set-ups large single crystals of SH2-pep- 
tide complexes were visible. These crystals were ve~ 
stable, and diffracted X-rays to high resolution (1.5 A 
on a laboratory X-ray source), enabling structure deter- 
mination to proceed. We now know that the phosphoty- 
rosine residue contributes the bulk of the binding energy 
in most SH2 interactions (Bradshaw and Waksman, 
2002), but at that time we thought hat a small miracle 
had occurred. 
David Cowburn and his colleagues provided one more 
critical boost to the Src project, without which the Src 
SH2 structure would never have been completed as 
rapidly as it was. In order to solve the crystal structure, 
we needed phases for the X-ray amplitudes. Today, for 
bacterially expressed protein, all the phases required to 
obtain a high quality electron density map might be 
obtained in a couple of hours at a synchrotron source 
using multi-wavelength anomalous diffraction (MAD) 
measurements from selenium-labeled protein crystals 
(Hendrickson, 2000). At that time, however, the MAD 
method had not come into general use, and neither 
had the techniques for minimizing radiation damage by 
collecting data at cryogenic temperatures. We at- 
tempted to solve the SH2 structure by forming heavy 
atom derivatives and using the method of multiple iso- 
morphous replacements (MIR), pioneered by Max Per- 
utz. Due to the inherent difficulties of this method our 
initial electron density maps were noisy and difficult o 
interpret. We could see the presence of two (x helices 
and a 13 sheet in the map, but the connectivity and 
direction of the secondary structural elements was not 
entirely clear. David Cowburn provided us with a de- 
tailed diagram, based on NMR (Overduin et al., 1992a), 
showing the hydrogen bonding pattern that character- 
izes the secondary structure of the Abl SH2 domain, the 
NMR structural analysis of which was nearing comple- 
tion at that time in his laboratory. Cowburn's diagram 
of the SH2 secondary structure was the key that allowed 
us to very rapidly complete a high resolution structure 
of the Src SH2 domain peptide complex without necessi- 
tating any further data collection. 1992 saw the simulta- 
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Figure 1. Reprint of Figure 4(A) of Waksman 
et al. (1993) 
A cutaway view of the Src SH2 domain show- 
ing the interactions with the high-affinity pep- 
tide. The accessible surface of the domain is 
represented by red dots and the polypeptide 
backbone of SH2 is shown as a purple ribbon. 
The peptide is shown as a space-filling 
model, with the phosphate group in white. 
neous publication of our paper on the Src SH2 domain 
phosphopeptide complex (Waksman et al., 1992), as 
well as two NMR structures of uncomplexed SH2 do- 
mains, that of Abl from the Cowburn lab (Overduin et 
al., 1992b) and that of PI 3-OH kinase from Campbell 
and coworkers (Booker et al., 1992). 
While our first structures of the Src SH2 domain ex- 
plained how these modules recognize phosphotyrosine, 
they provided no ready explanation for how particular 
SH2 domains recognize specific sequence contexts. 
Shortly after our first SH2 paper appeared, Lew Cantley 
told us that he and Songyang Zhou had mapped the 
sequence specificities of several SH2 domains using a 
peptide library approach. Given how the peptides bind 
in the Src SH2 structures we could generate models 
that explained the importance of residues located down- 
stream of the phosphotyrosine residue, and the hydro- 
phobicity and polarity of residues on the surface of the 
SH2 domain seemed to correlate with the observed pat- 
terns of specificities, such as that of the Src SH2 domain 
for peptides with the sequence Y'EEl, where Y* is phos- 
photyrosine. We wrote a short note on the results of our 
computer modeling and submitted it as a letter to the 
editor of Cell, hoping to have it published alongside the 
paper from Cantley and colleagues on SH2 specificity 
that had also been submitted to Cell. Benjamin Lewin, 
the founding editor of Cell, took a very long time to make 
up his mind about these papers, which perhaps reflects 
the fact that the importance of modular targeting units 
in eukaryotic signaling had barely begun to be recog- 
nized in the early 1990s. 
While these papers were incubating in the offices of 
Cell, Steve Shoelson at Harvard synthesized phospho- 
peptides corresponding to the optimal Src SH2 target 
identified by Cantley (containing the Y'EEl motif). Shoel- 
son provided these peptides to us and to Steve Harrison 
and Michael Eck at Harvard, who had been working 
independently on the SH2 domain of the Src kinase Lck. 
The synthesis of highly pure phosphotyrosyl peptides 
was an arcane art at that time, and Shoelson's peptides 
were crucial to the rapid and simultaneous determina- 
tion, both at Rockefeller and at Harvard, of SH2 domains 
bound to specific peptides and for helping to resolve 
doubts in Lewin's mind about the importance of the 
results (Eck et al., 1993; Waksman et al., 1993). These 
structures revealed the now canonical "two-pronged 
plug into two-holed socket" mode of peptide recognition 
by the Src and Lck SH2 domains (Figure 1), and set the 
stage for the rigorous mapping of the thermodynamics 
of SH2 target selectivity (reviewed in Bradshaw and 
Waksman, 2002). Four years later the Rockefeller and 
Harvard groups published the structures of assembled 
Src kinases, showing how the internal igation of the SH2 
domain holds these proteins in inactive conformations 
(Sicheri et al., 1997; Xu et al., 1997; see also Williams 
et al., 1997). 
When we were analyzing these first SH2 domains we 
found ourselves stretching for structural parallels to 
draw upon. Our initial comparison of the SH2 domain 
to proteases, immunoglobulins, or the MHC complex 
seems forced at best (Waksman et al., 1992), because 
the transient and relatively loose interaction between 
the SH2 domain and its targets seems rather different 
from the tight and long-lived complexes seen in these 
other systems. Today, the SH2 domain is one amongst 
many well-characterized peptide recognition domains 
that function in signaling, such as the SH3, PDZ, WW, 
PTB, and FHA domains, and its properties seem unre- 
markable (Pawson and Nash, 2003). Looking back, we 
are grateful to have had the opportunity to work on the 
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SH2 domain at a time before the stage lights brightened 
on the large cast of characters that ensure proper recog- 
nition of protein targeting signals and maintain fidelity 
and control in intracellular signaling. 
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Summary 
Polyoma T antigen immunoprecipitates contain a 
protein kinase-iike activity which preferentially 
phosphorylates material of 50-60,000 daltons mo- 
lecular weight. Phosphorylation is not diminished in 
extracts of polyoma tsA mutant-infected cells 
shifted to the nonpermissive temperature late in 
infection, conditions which inactivate the large T 
antigen. Phosphorylation is reduced or absent in 
cells infected with polyoma host range nontrans- 
forming (hr-t) mutants, which have defective small 
and medium T antigens. The major acceptor of 
phosphate is not the heavy chain of immunoglobu- 
lin, but appears to be the polyoma medium T anti- 
gen. The large T antigen is also phosphorylated, 
but usually to a lower specific activity. In terms of 
acid and alkali sensitivity and electrophoretic and 
chromatographic mobility in one and two dimen- 
sions, the phosphorylated residue behaves identi- 
cally to phosphotyrosine and differently than phos- 
phorylated serine, threonine, lysine and histidine. 
Introduction 
Cell transformation by polyoma virus involves at least 
two functions encoded in the early region of the viral 
genome (Eckhart, 1977; Fluck, Staneloni and Benja- 
min, 1977). The proteins encoded in the early region 
are referred to as T antigens, and have been identified 
by immunoprecipitation of extracts of lytically infected 
or transformed cells (TQrler and Salomon, 1977; Ito, 
Spurr and Dulbecco, 1977b; Hutchinson, Hunter and 
Eckhart, 1978; Schaffhausen, Silver and Benjamin, 
1978) or of the in vitro translation products of viral 
mRNA (Hunter, Hutchinson and Eckhart, 1978), using 
serum from tumor-bearing animals. There are at least 
three T antigens encoded by polyoma (Ito, Brockle- 
hurst and Dulbecco, 1977a; Smart and Ito, 1978; 
Hunter et al., 1978; Hutchinson et al., 1978; 
Schaffhausen et al., 1978), referred to as large, me- 
dium and small, with molecular weights of approxi- 
mately 90,000 (90K), 60,000 (60K) and 22,000 (22K) 
daltons, respectively. The three T antigens are en- 
coded by overlapping nucleotide sequences in the 
viral DNA: the small t antigen between 74 and 85 map 
units on the circular physical map (Griffin, Fried and 
Cowie, 1974) of polyoma DNA; the medium T antigen 
between 74 and 85 and 86 and 99 map units; and the 
large T antigen between 74 and 79 and 86 and 24 
map units (Smart and Ito, 1978; Hutchinson et al., 
1978; G. Carmichael and T. Benjamin, unpublished 
results). The medium and large T antigens are trans- 
lated in different reading frames from the viral DNA 
between 86 and 99 map units (Hunter et al., 1979). 
Two classes of mutants in the early region affect 
cell transformation: the temperature-sensitive (tsA) 
mutants (Fried, 1965) and the host range nontrans- 
forming (hr-t) mutants (Benjamin, 1970). The tsA mu- 
tants affect only the large T antigen (Ito et al., 1977b; 
Hutchinson et al., 1978); the hr-t mutants affect both 
the small and medium T antigens, but not the large T 
antigen (Schaffhausen et al., 1978). 
To understand the effects of the polyoma T antigens 
on cell growth regulation it will be necessary to identify 
their functions. The large T antigen is apparently 
responsible for the initiation of viral DNA replication 
(Francke and Eckhart, 1973) and affects the production 
of early mRNA (Cogen, 1978). The small and/or 
medium T antigens are not required for lytic infection, 
except under certain conditions (Goldman and Ben- 
jamin, 1975), but are required for abortive transfor- 
mation after infection (Schlegel and Benjamin, 1978). 
The gene product of Rous sarcoma virus responsi- 
ble for cell transformation (src) is associated with a 
protein kinase activity which phosphorylates the 
heavy chain of immunoglobulin in immunoprecipitates 
(Collett and Erikson, 1978; Levinson et al., 1978; 
RQbsamen, Friis and Bauer, 1979; Sefton, Hunter and 
Beemon, 1979). The related product of the endoge- 
nous cellular sarc gene also appears to be associated 
with a protein kinase activity (Collett et al., 1979; 
Oppermann et al., 1979). Immunoprecipitates of ad- 
enovirus T antigens contain a protein kinase activity 
(Lassam et al., 1979). A protein consisting of most of 
the SV40 large T antigen fused to a portion of an 
unidentified adenovirus protein contains ATPase and 
protein kinase activity (Tjian and Robbins, 1979), but 
the kinase activity separates from the bulk of the 
protein in highly purified preparations. We describe 
here a protein kinase-like activity present in immuno- 
precipitates of polyoma T antigens. The activity has 
the unusual specificity of phosphorylating tyrosine. 
Results 
Protein Kinase Activity in Immunoprecipitates 
To test for protein kinase activity in immunoprecipi- 
tates containing polyoma T antigens we infected 
mouse 3T6 cells with wild-type polyoma, harvested 
the infected cultures during the late phase of lytic 
infection, precipitated infected cell extracts with rat 
anti-tumor serum and incubated the immunoprecipi- 
tates with ~J2P-ATP. We then analyzed the distribu- 
tion of incorporated radioactivity by SDS-polyacryl- 
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Summary 
A phosphopeptide library was used to determine the 
sequence specificity of the peptide-binding sites of 
SH2 domains. One group of SH2 domains (Src, Fyn, 
Lck, Fgr, Abl, Crk, and Nck) preferred sequences with 
the general motif pTyr-hydrophilic-hydrophilic-Ile/Pro 
while another group (SH2 domains of 1385, phospho- 
lipase C-3,, and SHPTP2) selected the general motif 
pTyr-hydrophobic-X-hydrophobic. Individual members 
of these groups selected unique sequences, except 
the Src subfamily (Src, Fyn, Lck, and Fgr), which ell 
selected the sequence pTyr-Glu-Glu-lle. The variability 
in SH2 domain sequences at likely sites of contact pro- 
vides a structural basis for the phosphopepUde selec- 
tivity of these families. Possible in vivo binding sites 
of the SH2 domains are discussed. 
Introduction 
The discovery that Src homology 2 (SH2) domains provide 
phosphorylation-dependent and sequence-specific on- 
tacts for assembly of receptor signaling complexes has 
provided a breakthrough in understanding signal trans- 
duction (Cantley et al., 1991; Koch et al., 1991). This - 100 
amino acid sequence was first pointed out as a nonkinase 
domain conserved between the src and fps gene products 
likely to be involved in targeting (Sadowski et ai., 1986). 
Now more than 20 cytosolic proteins likely to be involved 
in signaling have been shown to contain SH2 domains. 
Recombinant SH2 domains from several different pro- 
teins, including Crk, phosphoinositide-specific phospholi- 
pase C type ~, (PLC-~), Ras GTPase-activating protein (Ras 
GAP), and Abl, have been shown to bind specifically to 
tyrosine-phosphorylated cellular proteins (Anderson et al., 
1990; Margolis et al., 1990; Mayer and Hanafusa, 1990; 
Mayer et al., 1991; Moran et al., 1990). Evidence that the 
binding of a particular SH2 domain to tyresine-phosphor- 
ylated proteins is dependent on the primary sequence 
around the phosphotyrosine (pTyr) came from a compari- 
son of the sequences of the regions of polyoma middle T 
and the plateiet-derived growth factor (PDGF) receptor 
that bind phosphatidylinositol 3-kinase (CanUey et al., 
1991). The sequence pTyr-MeWaI-X-Met was found at 
sites known to be critical for phosphatidylinositol 3-kinase 
binding to these proteins (Cohen et al., 1990; Kaziauskas 
and Cooper, 1989; Talmage et aL, 1989; Whitman et al., 
1985), and this sequence has been predictive for other 
receptors or receptor substrates that bind phosphatidyi- 
inositol 3-kinase (Lev et al., 1992; McGlade et al., 1992; 
Sun et al., 1991; Reedijk et ai., 1992). Synthetic phospho- 
peptides based on this sequence have been found to block 
phosphatidylinositol 3-1dnase binding to the PDGF recep- 
tor (Escobedo et al., 1991; Fantl et al., 1992) and to poly- 
oma middle T (Auger et al., 1992; Yoakim et al., 1992; 
Carpenter et ai., 1993). In addition, mutational studies 
have shown that the SH2 domains of phosphatidylinositol 
3-kinase, Ras GAP, and PLC--y recognize distinct phos- 
phopeptide sequences in the PDGF receptor (Fantl et al., 
1992; Kazlauskas et al., 1990, 1992). 
These studies have identified peptide sequences with 
high affinity for a few SH2 domains, yet systematic 
searches for optimal sequences for SH2 domains are 
needed. For example, peptides containing the sequence 
pTyr-Met/Val-X-Met have high affinity for phosphatidylino- 
sitol 3-kinase, and peptides with Gly, Ala, or Pro in place 
of the final Met have low affinity (Fantl et al., 1992). How- 
ever, the possibility that a peptide with 1 of the other 16 
amino acids at this position has an equal or higher affinity 
has not been tested. Here we demonstrate direct binding 
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Summary 
The crystal structure of the Src SH2 domain com- 
plexed with a high affinity l 1-residue phosphopep- 
tide has been determined at 2,7 A resolution by X-ray 
diffraction. The peptide binds in an extended confor- 
mation and makes primary interactions with the SH2 
domain at six central residues: PQ(pY)EEI. The phos- 
photyrosine and the isoleucine are tightly bound by 
two well-defined pockets on the protein surface, re- 
sulting in a complex that resembles a two-pronged 
plug engaging a two-holed socket. The glutamate resi- 
dues are in solvent-exposed environments in the vicin- 
ity of basic side chains of the SH2 domain, and the two 
N-terminal residues cap the phosphotyrosine-binding 
site. The crystal structure of Src SH2 in the absence 
of peptide has been determined at 2.5 A resolution, 
and comparison with the structure of the high affinity 
complex reveals only localized and relatively small 
changes. 
Introduction 
Src homology 2 (SH2) domains were first identified from 
sequence similarities in the noncatalytic regions of Src- 
related tyrosine kinases, spanning approximately 100 
amino acid residues (Sadowski et al., 1986). The subse- 
quent discovery that SH2 domains bind to specific phos- 
phorylated tyrosine residues has provided a link between 
tyrosine kinases and proteins that respond to tyrosine 
phosphorylation (for reviews see Koch et al., 1991; Paw- 
son and Gish, 1992; Mayer and Baltimore, 1993). The 
transmission of growth factor-mediated signals, for exam- 
ple, depends critically on the the sequence-specific recog- 
nition of phosphorylated tyrosines by SH2 domains, which 
have been discovered in a number of proteins that act 
downstream of growth factor receptors, including Ras 
GTPase-activating protein (GAP), phosphatidylinositol 
3'-kinase (PIK), and phospholipase C-~ (reviewed by Can- 
tley et al., 1991). SH2 domains serve to localize these 
proteins to activated receptors and are implicated in the 
modulation of enzymatic activity (O'Brien et al., 1990; 
Roussel et al., 1991; Backer et al., 1992). 
While SH2 domains share the common property of bind- 
ing phosphotyrosine-containing peptides, additional bio- 
logical specificity resides in the sequence contexts of the 
phosphotyrosine. This has been demonstrated clearly by 
the differential binding of the SH2 domains of proteins 
such as the p85 subunit of PIK, Ras GAP, and phospholi- 
pase C-~/to activated growth factor receptors (Moran et 
al., 1990; Birge et al., 1992; Fantl et al., 1992; Kashishian 
et al., 1992; Klippel et al., 1992; Rotin et al., 1992; Es- 
cobedo et al., 1991). The general architecture of SH2 do- 
mains and the mechanism of phosphotyrosine recognition 
have been clarified by crystal structures of Src SH2 do- 
main complexed with low affinity phosphopeptides 0Naks- 
man et al., 1992) and by nuclear magnetic resonance solu- 
tion structures of the uncomplexed forms of the SH2 
domains of the Abl tyrosine kinase (Overduin et al., 1992b) 
and the p85 subunit of PI 3'-OH kinase (Booker et al., 
1992). The two peptides used in the previous crystallo- 
graphic work bound Src SH2 rather weakly, with millimolar 
concentrations of peptide being required to compete for 
SH2 binding with phosphorylated epidermal growth factor 
receptor (Waksman et al., 1992). Thus, although highly 
specific interactions were observed between the SH2 do- 
main and the phosphotyrosine side chain, almost no inter- 
actions were seen between the rest of the peptide and 
the protein. This prevented the definition of the recognition 
sites for the flanking sequences, and the mechanism of 
sequence specificity remained an open question. 
From peptide competition and receptor mutagenesis ex- 
periments on the receptors for platelet-derived and epider- 
mal growth factors and the SH2 domains of p85, phospho- 
lipase C-% and GAP (Fantl et ai., 1992; Kashishian et al., 
1992; Rotin et al., 1992), it appears that short peptide se- 
quences suffice to capture the essential elements of se- 
quence-specific recognition. For example, the two SH2 
domains of p85~ bind to sequences in the platelet-derived 
growth factor receptor that contain methionine or valine at 
the first position following the phosphotyrosine, and methi- 
onine at the third position. In contrast, GAP binds most 
efficiently to a site in the platelet-derived growth factor 
receptor that contains methionine at the first position, with 
proline and tyrosine at the third and fourth positions, re- 
spectively (Fantl et al., 1992; Kashishian et al., 1992). 
The general question of sequence specificity in phos- 
phopeptide-SH2 interactions has been addressed re- 
cently by Cantley and coworkers, who used a screening 
method to select phosphopeptides that bind to any particu- 
lar SH2 domain, starting from a mixture of peptides that 
are degenerate at the three positions following the phos- 
photyrosine (Songyang et al., 1993 [this issue of Ce#]). 
This led to the identification of the motif pYEEI (more 
generally, two nonbasic polar residues following the phos- 
photyrosine and a large hydrophobic residue at the fourth 
position) as being optimal for binding to Src SH2. An 11- 
residue phosphotyrosyl peptide corresponding to a se- 
quence found in hamster middle T antigen (EPQpYEEI- 
PIYL) contains this motif and has been shown to bind Src 
SH2 with high affinity (estimated Ko = 3-6 nM) (Payne et 
al., submitted; Songyang et al., 1993). We refer to this 
peptide as YEEI. Previously, reported peptide binding 
